Glenn Nussdorf Net Worth

The estimated Net Worth of Glenn H Wisdom Starr Nussdorf is at least $218 million dollars as of 27 May 2021. Mr. Nussdorf owns over 3,887,500 units of Organogenesis stock worth over $153,182,067 and over the last 5 years he sold ORGO stock worth over $64,405,000. In addition, he makes $0 as Director at Organogenesis.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Nussdorf ORGO stock SEC Form 4 insiders trading

Glenn has made over 5 trades of the Organogenesis stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 3,887,500 units of ORGO stock worth $63,755,000 on 27 May 2021.

The largest trade he's ever made was selling 3,887,500 units of Organogenesis stock on 27 May 2021 worth over $63,755,000. On average, Glenn trades about 839,292 units every 105 days since 2019. As of 27 May 2021 he still owns at least 59,836,745 units of Organogenesis stock.

You can see the complete history of Mr. Nussdorf stock trades at the bottom of the page.

Glenn Nussdorf biography

Glenn H. Nussdorf serves as Director of the Company. Mr. Nussdorf has served as Chief Executive Officer of Quality King Distributors, Inc., a distributor of health and beauty care products and prescription drugs, and its subsidiary QK Healthcare, Inc., since 1999. Previously, Mr. Nussdorf served as Chief Operating Officer of Quality King from 1997 to 1998 and as a Senior Vice President from 1994 to 1996. Mr. Nussdorf is also a major shareholder of Perfumania Holdings, Inc., a vertically integrated wholesale distributor and specialty retailer of perfumes and fragrances. Since 2017, Mr. Nussdorf has also served as a member of the board of directors of Perfumania Holdings, Inc.

How old is Glenn Nussdorf?

Glenn Nussdorf is 65, he's been the Director of Organogenesis since 2003. There are 5 older and 13 younger executives at Organogenesis. The oldest executive at Organogenesis Holdings Inc. is Alan Ades, 81, who is the Independent Director.

What's Glenn Nussdorf's mailing address?

Glenn's mailing address filed with the SEC is 35 SAWGRASS DRIVE44 WILSON STREET, , BELLPORTHARTSDALE, NYNY, 1171310530.

Insiders trading at Organogenesis

Over the last 5 years, insiders at Organogenesis have traded over $157,938,506 worth of Organogenesis stock and bought 15,146,267 units worth $65,732,558 . The most active insiders traders include Capital Managing Member Iv,..., Alan A.Erani Albert Erani D... et Glenn H Wisdom Starr Nussdorf. On average, Organogenesis executives and independent directors trade stock every 24 days with the average trade being worth of $1,067,103. The most recent stock trade was executed by Patrick Bilbo on 28 March 2024, trading 152,250 units of ORGO stock currently worth $179,655.

What does Organogenesis do?

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds. Its surgical and sports medicine products comprise NuCel, a surgically implanted allograft used primarily in spinal and orthopedic surgical applications; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor, a chorionic membrane wound covering; TransCyte, a bioengineered tissue for the treatment of partial thickness burns; and Gintuit, a bioengineered bi-layered living cellular tissue for the treatment of mucogingival conditions in adults. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

Complete history of Mr. Nussdorf stock trades at Organogenesis

Organogenesis executives and stock owners

Organogenesis executives and other stock owners filed with the SEC include:

• Gary S. Gillheeney Sr.,
  Pres, CEO & Director
• Gary Gillheeney,
  President, Chief Executive Officer, Director
• Brian Grow,
  Chief Commercial Officer
• Brian Grow,
  Chief Commercial Officer
• Lori Freedman,
  Vice President, General Counsel
• Wayne Mackie,
  Independent Director
• Arthur Leibowitz,
  Independent Director
• Joshua Tamaroff,
  Independent Director
• Mike Piccinino,
  IR Contact Officer
• Albert Erani,
  Independent Director
• Alan Ades,
  Independent Director
• Glenn Nussdorf,
  Director
• Maurice Ades,
  Director
• Antonio Montecalvo,
  Vice President - Health Policy and Contracting
• Patrick Bilbo,
  Chief Operating Officer
• Henry Hagopian,
  Interim Chief Financial Officer, Vice President - Finance, Treasurer
• Kurt Matheson,
  VP of Marketing
• Lori H. Freedman,
  VP & Gen. Counsel
• William R. Kolb CPA,
  Sec.
• Henry Hagopian III,
  Sr. VP of Fin. & Treasurer
• Dr. Zorina Pitkin,
  Sr. VP of Quality Systems
• Thomas L. Pearl,
  VP of HR
• Patrick Bilbo,
  Chief Operating Officer
• David C. Francisco,
  Chief Financial Officer
• Erani Family Trust Dated 12...,
  
• Albert Wisdom Starr Erani,
  
• Glenn H Erani Dennis Albert...,
  
• 2016 Organo 10 Year Grat U/...,
  
• Erani 2012 Issue Trust Date...,
  
• Dennis Gn 2016 Organo 10 Ye...,
  
• Jon L Giacomin,
  Director
• Prathyusha Duraibabu,
  Director
• Capital Managing Member Iv,...,
  
• Michael W Katz,
  10% owner
• Timothy M. Cunningham,
  Chief Financial Officer
• David Francisco,
  Chief Financial Officer
• Michael Joseph Driscoll,
  Director
• Starr Wisdom,
  10% owner
• Dennis Erani,
  10% owner
• Erani Family Trust Dated 12...,
  
• Robert Cavorsi,
  Vice President, Strategy
• Holdings, Llcgn 2016 Organo...,
  
• Gilberto Quintero,
  Director
• Michele Ilene Korfin,
  Director
• Albertnussdorf Glenn H Denn...,
  
• Albertred Holdings, Llcgn 2...,